Angiogenesis and Ovarian Cancer

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2009 Sep 25

PMID 19775995

Citations 33

Authors

Cesar Gomez-Raposo

Marta Mendiola

Jorge Barriuso

Enrique Casado

David Hardisson

Andres Redondo

Affiliations

Soon will be listed here.

Abstract

Ovarian carcinoma is the most important cause of gynaecological cancer-related mortality in Western societies. The age at diagnosis, extent of disease (as expressed by FIGO state), success of primary surgery and the histopathological features of the tumour are important prognostic markers. The majority of patients with ovarian cancer present with advanced disease (FIGO stage III/IV) and in this group of patients the median survival is only three years. New treatment approaches are therefore required to improve outcome in this disease. Angiogenesis, the development of a neovascular blood supply, is a critical step in the propagation of malignant tumour growth and metastasis and represents a promising target. This review will focus on angiogenesis, VEGF biology and the potential value of angiogenic factors with prognostic value in ovarian cancer.

Citing Articles

Alternative splicing in ovarian cancer.

Wei L, Li Y, Chen J, Wang Y, Wu J, Yang H Cell Commun Signal. 2024; 22(1):507.

PMID: 39425166 PMC: 11488268. DOI: 10.1186/s12964-024-01880-8.

Deregulated circRNAs in Epithelial Ovarian Cancer With Activity in Preclinical Models: Identification of Targets and New Modalities for Therapeutic Intervention.

Weidle U, Birzele F Cancer Genomics Proteomics. 2024; 21(3):213-237.

PMID: 38670587 PMC: 11059596. DOI: 10.21873/cgp.20442.

ANGPTL4 accelerates ovarian serous cystadenocarcinoma carcinogenesis and angiogenesis in the tumor microenvironment by activating the JAK2/STAT3 pathway and interacting with ESM1.

Li Y, Gao A, Zeng T, Liu D, Zhang Q, Ran X J Transl Med. 2024; 22(1):46.

PMID: 38212795 PMC: 10785435. DOI: 10.1186/s12967-023-04819-8.

Therapeutic effects on cancer of the active ingredients in rhizoma paridis.

Li J, Jia J, Zhu W, Chen J, Zheng Q, Li D Front Pharmacol. 2023; 14:1095786.

PMID: 36895945 PMC: 9989034. DOI: 10.3389/fphar.2023.1095786.

Do Aging and Parity Affect VEGF-A/VEGFR Content and Signaling in the Ovary?-A Mouse Model Study.

Di Nisio V, Rossi G, Chiominto A, Pompili E, Cecconi S Int J Mol Sci. 2023; 24(4).

PMID: 36834730 PMC: 9966908. DOI: 10.3390/ijms24043318.

References

Nishida N, Yano H, Komai K, Nishida T, Kamura T, Kojiro M . Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer. 2004; 101(6):1364-74. DOI: 10.1002/cncr.20449. View

Wu Q, Suo Z, Kristensen G, Baekelandt M, Nesland J . The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma. Gynecol Oncol. 2006; 102(1):15-21. DOI: 10.1016/j.ygyno.2005.11.034. View

Goodheart M, Ritchie J, Rose S, Fruehauf J, De Young B, Buller R . The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res. 2005; 11(10):3733-42. DOI: 10.1158/1078-0432.CCR-04-0056. View

Ogawa S, Kaku T, Kobayashi H, Hirakawa T, Ohishi Y, Kinukawa N . Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma. Cancer Lett. 2002; 176(1):111-8. DOI: 10.1016/s0304-3835(01)00754-6. View

Osada R, Horiuchi A, Kikuchi N, Ohira S, Ota M, Katsuyama Y . Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor.... Hum Pathol. 2006; 37(11):1414-25. DOI: 10.1016/j.humpath.2006.04.031. View

Fan F, Wey J, McCarty M, Belcheva A, Liu W, Bauer T . Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene. 2005; 24(16):2647-53. DOI: 10.1038/sj.onc.1208246. View

Faix J, Niloff J, Tognazzi K, Manseau E, Dvorak H, Brown L . Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest. 1996; 74(6):1105-15. View

Yamamoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K . Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer. 1997; 76(9):1221-7. PMC: 2228134. DOI: 10.1038/bjc.1997.537. View

Ferrara N . The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat. 1995; 36(2):127-37. DOI: 10.1007/BF00666035. View

10.

Sariban E, Sitaras N, Antoniades H, Kufe D, Pantazis P . Expression of platelet-derived growth factor (PDGF)-related transcripts and synthesis of biologically active PDGF-like proteins by human malignant epithelial cell lines. J Clin Invest. 1988; 82(4):1157-64. PMC: 442665. DOI: 10.1172/JCI113712. View

11.

Trinh X, Tjalma W, Vermeulen P, Van den Eynden G, Van der Auwera I, Van Laere S . The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer. 2009; 100(6):971-8. PMC: 2661789. DOI: 10.1038/sj.bjc.6604921. View

12.

Barton D, Cai A, Wendt K, Young M, Gamero A, De Cesare S . Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res. 1998; 3(9):1579-86. View

13.

Engels K, Bois A, Harter P, Fisseler-Eckhoff A, Kommoss F, Stauber R . VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection. J Clin Pathol. 2009; 62(5):448-54. DOI: 10.1136/jcp.2008.063859. View

14.

Rosano L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A . Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci U S A. 2009; 106(8):2806-11. PMC: 2650347. DOI: 10.1073/pnas.0807158106. View

15.

Taskiran C, Erdem O, Onan A, Arisoy O, Acar A, Vural C . The prognostic value of endoglin (CD105) expression in ovarian carcinoma. Int J Gynecol Cancer. 2006; 16(5):1789-93. DOI: 10.1111/j.1525-1438.2006.00658.x. View

16.

Vermeulen P, Gasparini G, Fox S, Colpaert C, Marson L, Gion M . Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer. 2002; 38(12):1564-79. DOI: 10.1016/s0959-8049(02)00094-1. View

17.

Paley P, Staskus K, GEBHARD K, Mohanraj D, Twiggs L, Carson L . Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer. 1997; 80(1):98-106. DOI: 10.1002/(sici)1097-0142(19970701)80:1<98::aid-cncr13>3.0.co;2-a. View

18.

Masood R, Cai J, Zheng T, Smith D, Hinton D, Gill P . Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood. 2001; 98(6):1904-13. DOI: 10.1182/blood.v98.6.1904. View

19.

Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86(3):353-64. DOI: 10.1016/s0092-8674(00)80108-7. View

20.

Hartenbach E, Olson T, Goswitz J, Mohanraj D, Twiggs L, Carson L . Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett. 1998; 121(2):169-75. DOI: 10.1016/s0304-3835(97)00350-9. View